3,328,590Due to related party3,287,582- Accounts payable and accrued liabilities 26,259,56024,777,808Income tax payable 243,071238,775Deferred revenue7,541,5151,378,425 Deferred government grants 438,853431,097Total current liabilities50,384,54830,154,695Deferred government grants 4,571,8384,068,602Loans payable36,229,00731,181,235Due to related party -3,230,125Deferred revenue-10,693,247Total long term liabilities40,800,84549,173,209Total liabilities91,185,39379,327,904Commitments and contingencies EQUITYPreferred stock-- Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nilCommon stock55,40355,092 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 55,402,061 (2012 – 55,091,561)Additional paid-in capital107,201,859106,245,934Accumulated other comprehensive income13,205,20311,770,927Statutory surplus reserves11,808,27111,808,271Accumulated deficit -10,535,905-12,156,414Total stockholders' equity121,734,831117,723,810Non-controlling interests 12,683,29911,711,553Total equity134,418,130129,435,363Total liabilities and equity$225,603,523$208,763,267
SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Income (Loss) and Comprehensive Income (Loss)Three and Nine Months Ended September 30, 2013 and 2012(Unaudited)(Expressed in U.S. Dollars)Three months endedNine months e
|SOURCE Sinovac Biotech Ltd.|
Copyright©2012 PR Newswire.
All rights reserved